Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Gastroenterology Disorders & Therapy Volume 5 (2018), Article ID 5:IJGDT-137, 5 pages
https://doi.org/10.15344/2393-8498/2018/137
Mini Review
Primary Omental Gastrointestinal Stromal Tumor-What We Know and How Can We Deal With it, Based on Case Series and Review of Literature

Magda Alves1*, Nuno Bentes2, Tiago Louro2, Nádia Gonçalves3 and John Keohane4

1General Surgery Department, Hospital Vila Franca de Xira, Portugal
2Junior Consultant, General Surgery Department, Hospital Vila Franca Xira, Portugal
3Senior Consultant, General Surgery Department, Hospital Vila Franca de Xira, Portugal
4Senior Consultant, Mercy Cork Hospital, Ireland
Dr. Magda Alves, General Surgery Department, Hospital Vila Franca de Xira, Portugal; E-mail: alves.magda0@gmail.com
23 November 2017; 20 March 2018; 22 March 2018
Alves M, Bentes N, Louro T, Gonçalves N, Keohane J, et al. (2018) Primary Omental Gastrointestinal Stromal Tumor- What We Know and How Can We Deal With it, Based on Case Series and Review of Literature. Int J Gastroenterol Disord Ther 5: 137. doi: https://doi.org/10.15344/2393-8498/2018/137
© 2018 Alves et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Feng F, Tian Y, Liu Z, Liu S, Xu G, et al. (2016) Clinicopathological features and prognosis of omental gastrointestinal stromal tumor: evaluation of pooled case series. Scientific Reports 6: 30748. View
  2. Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, et al. (2012) Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13: 265-274. View
  3. Postow MA, Robson ME (2012) Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clin Sarcoma Res 2: 16. View
  4. Yi JH, Park BB, Kang JH, Hwang IG, Shin DB, et al. (2015) Retrospective analysis of extra-gastrointestinal stromal tumors. World Journal of Gastroenterology 21: 1845-1850. View
  5. Lasota J, Miettinen M (2006) KIT and PDGFRA mutations in gastrointestinal stromal tumos (GISTs). Semin Diagn Pathol 23: 91-102. View
  6. Miettinen M, Sobin LH, Lasota J (2009) Gastrointestinal Stromal tumors presenting as Omental Masses- a clinicopathologic analysis of 95 cases. Am J Surg Pathol 33: 1267-1275. View
  7. Fagkrezos D, Touloumis Z, Giannila M, Penlidis C, Papaparaskeva K, et al. (2012) Extra-gastrointestinal stromal tumor of the omentum: a rare case report and reviw of the literature. Rare Tumors 4: 44. View
  8. Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal Stromal tumors of the stomach; a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow up. Am J Surg Pathol 29: 52-68. View
  9. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58. View
  10. Sakurai S, Hishima T, Takazawa Y, Sano T, Nakajima T, et al. (2001) Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol Int 51: 524-531. View
  11. Dedemadi G, Georgoulis G, Kontopanos D, Anagnostou E, Morphopoulos G, et al. (2009) Extragastrointestinal stromal tumors of the omentum: review apropos of a case with a novel gain-of-function KIT mutation. J Gastrointest Cancer 40: 73-78. View
  12. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PC (2001) The histopathological differential diagnosis of gastrointestinal stromal tumors. J Clin Pathol 54: 96-102. View
  13. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 11: 728-734. View
  14. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol lab Med 130: 1466-1478. View
  15. Blanke CD, Corless CL (2005) State-of-the-art therapy for gastrointestinal stromal tumors. Cancer Invest 23: 274-280. View
  16. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, et al. (1998) Gainof- function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580. View
  17. Miettinen M, Makhlouf H, Sobin LH, Lasota J (2006) Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum- a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. Am J Surg Pathol 30: 477-489. View
  18. Gutierrez JC, Oliveira LOP, Perez EA, Rocha-Lima C, Livingstone AS, et al. (2007) Optimazing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coll Surg 205: 479-491. View
  19. Valsangkar N, Sehdev A, Misra S, Zimmers TA, O'Neil BH, et al. (2015) Current management of gastrointestinal stromal tumors: surgery, current biomarkers, mutations, and therapy. Surgery 158: 1149-1164. View
  20. Yoshikawa K, Shimada M, Kurita N, Sato H, Iwata T, et al. (2013) Efficacy of PET-CT for predicting the malignant potential of gastrointestinal stromal tumors. Surg Today 43: 1162-1167. View
  21. DeWitt J, Emerson RE, Sherman S, Al-Haddad M, McHenry L, et al. (2011) Endoscopic ultrasound-guided Trucut biopsy of gastrointestinal mesenchymal tumor. Surg Endosc 25: 2192-2202. View
  22. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer Suppl 5: S60-S65. View
  23. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760- 1764. View
  24. Balachandran VP, DeMatteo RP (2014) Gastrointestinal stromal tumor: who should get imatinib and how long? Adv Surg 48: 165-183. View
  25. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK, et al. (2016) The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 19: 3-14. View
  26. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480. View
  27. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360- 5367. View
  28. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumors after failure of imatinib: a randomized controlled trial. Lancet 368: 1329-1338. View
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.